Overview

Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix)

Status:
Active, not recruiting

Trial end date:
2021-12-02

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy, safety and tolerability of various doses and durations of linezolid plus bedaquiline and pretomanid after 26 weeks of treatment in participants with either pulmonary XDR-TB, pre-XDR-TB, or treatment intolerant or non-responsive MDR-TB.

Phase:

Phase 3

Details

Lead Sponsor:

Global Alliance for TB Drug Development

Treatments:

Bedaquiline
Diarylquinolines
Linezolid